The future of stroke therapy must not be mired by past arguments.
NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford OX3 7LE, UK; Oxford Medical School, University of Oxford, Oxford, UK; Radcliffe Department of Medicine, University of Oxford, Oxford, UK. Electronic address: alastair.buchan@medsci.ox.ac.uk.
Alastair M
AM
Buchan
Oxford Medical School, University of Oxford, Oxford, UK.
Hasneen G
HG
Karbalai
Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Brad A
BA
Sutherland
D003131:Combined Modality Therapy; D042241:Early Diagnosis; D057510:Endovascular Procedures; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015607:Stents; D020521:Stroke / Q000175:diagnosis / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator